Last updated on February 2018

A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART


Brief description of study

A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.

Clinical Study Identifier: NCT02259127

Find a site near you

Start Over

Kid-Cru

Parow, South Africa
  Connect »

PHRU

Soweto, South Africa
  Connect »

JCRC

Kampala, Uganda
  Connect »

MUJHU

Kampala, Uganda
  Connect »

JCRC

Mbarara, Uganda
  Connect »

UZCRC

Harare, Zimbabwe
  Connect »